Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408724 | 0.85 | DGAT1 (0.46) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL408273 | 0.84 | DGAT1 (0.54) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL4486967 | 0.82 | DGAT1 (0.52) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL3829929 | 0.81 | NOTUM (0.48) | HTTDGAT1 | |
| SCHEMBL4296607 | 0.80 | DGAT1 (0.68) | DGAT1 | |
| SCHEMBL408677 | 0.80 | NOTUM (0.42) | ALDH1A1DGAT1 | |
| SCHEMBL28192192 | 0.79 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1MAPTHTTMEN1 | |
| SCHEMBL4294988 | 0.77 | DGAT1 (0.55) | SMN1; SMN2ALDH1A1MAPTKDM4EDGAT1 | |
| SCHEMBL4500053 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1MAPTHTTMEN1 | |
| SCHEMBL408727 | 0.76 | DGAT1 (0.39) | SMN1; SMN2ALDH1A1KDM4EDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589116-B2 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2009-09-15 | — | — | US | disclosed |
| CN-101333192-A | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO INC (US) | 2008-12-31 | — | — | CN | disclosed |
| EP-1615895-A4 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO INC (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| CN-1798738-A | Biaryl substituted pyrazoles as sodium channel blockers | MERCK & CO INC (US) | 2006-07-05 | — | — | CN | disclosed |
| EP-1615895-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092140-A1 | BIARYL SUBSTITUTED PYRAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183785-A1 | Biaryl substituted pyrazoles as sodium channel blockers | TRPV1, TRPA1, TRPV3 | SMN1; SMN2 836/4885ALDH1A1 995/4885MAPT 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.